Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 14 May 2019, 09:12 HKT/SGT
Share:
    

Source: NEC Corporation
NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.


Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511


Topic: Press release summary
Source: NEC Corporation

Sectors: Cloud & Enterprise, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
May 17, 2024 10:19 HKT/SGT
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 8, 2024 09:24 HKT/SGT
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement
Apr 24, 2024 12:25 HKT/SGT
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 22, 2024 14:09 HKT/SGT
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 11, 2024 14:10 HKT/SGT
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
Apr 10, 2024 12:36 HKT/SGT
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 8, 2024 12:45 HKT/SGT
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Mar 25, 2024 09:08 HKT/SGT
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
Mar 22, 2024 07:38 HKT/SGT
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
Mar 21, 2024 09:02 HKT/SGT
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: